. 2021 May 7;23(6):55. doi: 10.1007/s11886-021-01487-2

Table 2.

Meta-analysis of randomized clinical trials on remote monitoring of cardiac implantable electronic devices from various device manufacturers: effects on mortality, hospitalizations, and visits

Meta-analysis	RM system	Sample size (n)	Average follow-up^a (Months)	No of studies included	Primary endpoint	Results
Parthiban et al. (2015) [87]	HM, CLN	4932 5372	14.4 NA	7 7	• All-cause mortality (RM vs. CG) • Hospitalizations (RM vs. CG)	• OR 0.83 (95% CI 0.58-1.17) • OR 0.83 (95% CI 0.63-1.10)
Klersy et al., (2016) [88••]	HM, CLN	5702	12-36	11	• Reduction in total number of visits (RM vs. CG) • Cardiac hospitalizations (RM vs. CG) • Composite of emergency room, unplanned hospital visits, or hospitalizations (RM vs. CG)	• RR 0.56 (95% CI 0.43-0.73) • RR 0.96 (95% CI 0.82-1.12) • RR 0.99 (95% CI 0.68-1.43)

Meta-analysis

RM system

Sample size (n)

Average
follow-up^a
(Months)

No of studies included

Primary endpoint

Results

Parthiban et al. (2015) [87]

HM, CLN

4932

5372

14.4

• All-cause mortality (RM vs. CG)

• Hospitalizations (RM vs. CG)

• OR 0.83 (95% CI 0.58-1.17)

• OR 0.83 (95% CI 0.63-1.10)

Klersy et al., (2016) [88••]

HM, CLN

5702

12-36

• Reduction in total number of visits (RM vs. CG)

• Cardiac hospitalizations (RM vs. CG)

• Composite of emergency room, unplanned hospital visits, or hospitalizations (RM vs. CG)

• RR 0.56 (95% CI 0.43-0.73)

• RR 0.96 (95% CI 0.82-1.12)

• RR 0.99 (95% CI 0.68-1.43)

CI confidence interval, CLN CareLink Network (Medtronic Inc.; Minneapolis and Tempe, USA), CG control group, HM Home Monitoring (Biotronik SE & Co. KG; Berlin, Germany), No number, NA not available, OR odds ratio, RM, remote monitoring, RR, relative risk

^aMean or median, whatever provided in the original publication